A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

AMRA Medical and Fulcrum Therapeutics Develop MRI Method for Multi-site Neuromuscular Clinical Trials

Clinical trial investigators commonly use functional tests such as the 6-Minute Walk Test and single-slice MRI to evaluate neuromuscular disease progression. These techniques can vary substantially, creating unwanted data noise – potentially making trials larger, longer and more costly. Additionally, there is a lack of standards for implementing whole-body MRI in multi-center trials, making it challenging to quantify how the disease affects individual muscles throughout the body in different stages of the disease. Lastly, neuromuscular disease studies often emphasize only the legs.  This study includes whole muscle volumes in the legs, trunk, shoulders, and arms.

AMRA Medical and Fulcrum conducted a study to evaluate, optimize and standardize a whole-body MRI protocol for use in clinical trials for Fulcrum’s losmapimod – a small molecule investigational therapeutic for FSHD. Together, they successfully developed a detailed musculoskeletal MRI protocol to quantify muscle fat fraction, lean muscle volume, and muscle fat infiltration. They volumetrically and bilaterally analyzed 18 individual muscles in 16 adults with FSHD across 6 clinical sites using diverse MRI scanner manufacturers. Fulcrum recognizes that AMRA’s technology is a significant advancement in neuromuscular clinical trials and plans to use this protocol as part of the further development of losmapimod.

Diego Cadavid, Fulcrum Therapeutics’ Senior Vice President of Clinical Development says, “Commonly used endpoints – such as functional tests – have limitations, so we engaged with AMRA based on their ability to reliably and quickly segment and quantify muscles. Together we developed an MRI protocol that generates stable images from which AMRA’s algorithms produce consistent, quality, objective and reproducible biomarkers that we now use in our ongoing clinical trial program.”

This study further demonstrates that AMRA’s MRI technology:  1) has the potential to follow heterogeneous disease distribution; 2) is compatible with major MRI scanner manufacturers, making multicenter trials more feasible; 3) can perform whole-body 3D volumetric measurements of individual muscles and muscle groups, enabling earlier and more accurate detection of fat and muscle changes; and 4) can longitudinally monitor several different muscles specific to the neuromuscular disorder and patient.

These results rationalize the exploration and use of AMRA’s methods in additional neuromuscular clinical trials. The full abstract for Development and Evaluation of a Whole-Body MRI Imaging Protocol And Analysis Algorithms to Measure Changes in Skeletal Muscle in FSHD (#142) can be viewed on the MDA 2020 website.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy